Skip Navigation



Annals of Oncology Advance Access published online on October 13, 2009
Annals of Oncology, doi:10.1093/annonc/mdp396
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kwan, W.
Right arrow Articles by Olivotto, I. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwan, W.
Right arrow Articles by Olivotto, I. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1–2pN0 disease?

W. Kwan1,*, A. J. Al-Tourah2, C. Speers3, R. Woods3, H. Kennecke4 and I. A. Olivotto5

1 Radiation Therapy Program, Fraser Valley Centre
2 Systemic Therapy Program, Fraser Valley Centre
3 Breast Cancer Outcomes Unit
4 Systemic Therapy Program, Vancouver Centre
5 Radiation Therapy Program, Vancouver Island Centre, BC Cancer Agency, British Columbia, Canada

* Correspondence to: Dr W. Kwan, Fraser Valley Centre, BC Cancer Agency, 13750 96th Avenue, Surrey, British Columbia, Canada V3V 1Z2. Tel: +1-604-930-4085; Fax: +1-604-930-4065; E-mail: wkwan{at}bccancer.bc.ca

Background: The impact of HER2 overexpression on the locoregional control of breast cancer is controversial.

Patients and methods: Data on 906 women diagnosed with pT1–2pN0 breast cancer from 1986 to 1992 with known HER2 status and treated with a modified radical mastectomy without adjuvant radiotherapy or adjuvant trastuzumab were analyzed with respect to local relapse-free survival (LRFS), regional relapse-free survival (RRFS) and distant relapse-free survival (DRFS). Log-rank statistics were used to compare 10-year Kaplan–Meier curves of LRFS, RRFS and DRFS in HER2+ and HER2– patients.

Results: Median follow-up was 12.8 years. HER2+ patients had a worse DRFS (P = 0.028) but there was no statistically significant difference in LRFS or RRFS between HER2+ and HER2– patients (P = 0.32 and 0.24 for LRFS and RRFS, respectively). Ten-year LRFS estimates among HER2+ patients was 91.3% and 86.9% for HER2– patients. Ten-year RRFS estimates for HER2+ and HER2– patients were 88.0% and 93.0%, respectively.

Conclusion: HER2 overexpression was not associated with higher local or regional recurrence risk in subjects with pT1–2pN0 breast cancer following mastectomy and nodal dissection after a median follow-up of >12 years.

breast cancer, HER2 status, locoregional control

Received for publication February 24, 2009. Revision received May 12, 2009. Revision received June 25, 2009. Accepted for publication July 8, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.